CY1110921T1 - Υποδοχεας κυτοκινης zcytor19 - Google Patents

Υποδοχεας κυτοκινης zcytor19

Info

Publication number
CY1110921T1
CY1110921T1 CY20101100038T CY101100038T CY1110921T1 CY 1110921 T1 CY1110921 T1 CY 1110921T1 CY 20101100038 T CY20101100038 T CY 20101100038T CY 101100038 T CY101100038 T CY 101100038T CY 1110921 T1 CY1110921 T1 CY 1110921T1
Authority
CY
Cyprus
Prior art keywords
polypeptides
methods
vitro
vivo
zcytor19
Prior art date
Application number
CY20101100038T
Other languages
English (en)
Inventor
Scott R Presnell
Wenfeng Xu
Julia E Novak
Theodore E Whitmore
Francis J Grant
Original Assignee
Zymogenetics, L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, L.L.C. filed Critical Zymogenetics, L.L.C.
Publication of CY1110921T1 publication Critical patent/CY1110921T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)

Abstract

Παρουσιάζονται νέα πολυπεπτίδια, πολυνουκλεοτίδια που κωδικεύουν τα πολυπεπτίδια, και σχετιζόμενες συνθέσεις και μέθοδοι για zcytor19, ένα νέο υποδοχέα κυτοκίνης κατηγορίας II. Τα πολυπεπτίδια μπορούν να χρησιμοποιηθούν στο πλαίσιο μεθόδων ανίχνευσης συνδετών που διεγείρουν τον πολλαπλασιασμό και/ή ανάπτυξη αιμοποιητικών, λεμφικών και μυελοειδών κυττάρων in vitro και in vivo. Τα πολυπεπτίδια υποδοχέα δέσμευσης συνδέτη μπορούν επίσης να χρησιμοποιηθούν για τον αποκλεισμό της ενεργότητας συνδέτη in vitro και in vivo. Τα πολυνουκλεοτίδια που κωδικεύουν τον zcytor19 εντοπίζονται στο χρωμόσωμα 1p36.11, και μπορούν να χρησιμοποιηθούν για την ταυτοποίηση περιοχής του γονιδιώματος που συνδέεται με παθολογικές καταστάσεις στον άνθρωπο. Η παρούσα εφεύρεση επίσης περιλαμβάνει μεθόδους για την παραγωγή της πρωτεΐνης, χρήσεις αυτής και αντισώματα έναντι αυτής.
CY20101100038T 2000-11-28 2010-01-14 Υποδοχεας κυτοκινης zcytor19 CY1110921T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US26721101P 2001-02-07 2001-02-07
EP01988203A EP1356046B1 (en) 2000-11-28 2001-11-28 Cytokine receptor zcytor19

Publications (1)

Publication Number Publication Date
CY1110921T1 true CY1110921T1 (el) 2015-06-10

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100038T CY1110921T1 (el) 2000-11-28 2010-01-14 Υποδοχεας κυτοκινης zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (el)
EP (1) EP1356046B1 (el)
JP (1) JP2004532611A (el)
AT (1) ATE445701T1 (el)
AU (1) AU2002241533A1 (el)
CA (1) CA2430485A1 (el)
CY (1) CY1110921T1 (el)
DE (1) DE60140213D1 (el)
DK (1) DK1356046T3 (el)
ES (1) ES2334888T3 (el)
PT (1) PT1356046E (el)
WO (1) WO2002044209A2 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
CN101676728A (zh) 2002-04-19 2010-03-24 津莫吉尼蒂克斯公司 细胞因子受体
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
EP1927600A1 (en) 2003-08-07 2008-06-04 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
CA2574564C (en) 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
ES2915698T3 (es) * 2009-04-01 2022-06-24 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
MX2013014773A (es) * 2011-06-13 2014-01-20 Merck Sharp & Dohme Procedimiento de purificacion de formas nativas o mutantes de la toxina difterica.
HUE047856T2 (hu) 2011-12-13 2020-05-28 Bial Portela & Ca Sa Kémiai vegyület, amely köztitermékként használható katechol-O-metil-transzferáz inhibitor elõállításához
NZ630888A (en) * 2013-03-15 2017-06-30 Abbvie Inc Antibody drug conjugate (adc) purification
WO2014182658A1 (en) * 2013-05-06 2014-11-13 Abbvie Inc. Compositions for cell culture and methods of using the same
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
KR102466763B1 (ko) * 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
WO2023049774A1 (en) * 2021-09-21 2023-03-30 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU6069300A (en) 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
EP2298789B1 (en) * 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
US20030027253A1 (en) * 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
CN101531715A (zh) * 2001-04-20 2009-09-16 津莫吉尼蒂克斯公司 细胞因子蛋白质家族
JPWO2003031620A1 (ja) 2001-10-02 2005-01-27 持田製薬株式会社 新規クラスｉｉサイトカイン受容体
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
CN101676728A (zh) * 2002-04-19 2010-03-24 津莫吉尼蒂克斯公司 细胞因子受体
EP1575609A4 (en) 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer

Also Published As

Publication number Publication date
ES2334888T3 (es) 2010-03-17
EP1356046B1 (en) 2009-10-14
US20030027253A1 (en) 2003-02-06
DE60140213D1 (de) 2009-11-26
EP1356046A2 (en) 2003-10-29
US20070048846A1 (en) 2007-03-01
WO2002044209A2 (en) 2002-06-06
CA2430485A1 (en) 2002-06-06
DK1356046T3 (da) 2010-03-01
US7618791B2 (en) 2009-11-17
US7601809B2 (en) 2009-10-13
US20120064571A1 (en) 2012-03-15
ATE445701T1 (de) 2009-10-15
PT1356046E (pt) 2010-03-09
US20070111942A1 (en) 2007-05-17
US20140248661A1 (en) 2014-09-04
US20110091876A1 (en) 2011-04-21
US20070048804A1 (en) 2007-03-01
AU2002241533A1 (en) 2002-06-11
US20050266485A1 (en) 2005-12-01
US20070048799A1 (en) 2007-03-01
US7608452B2 (en) 2009-10-27
JP2004532611A (ja) 2004-10-28
WO2002044209A3 (en) 2003-08-21
US20070117165A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
CY1110921T1 (el) Υποδοχεας κυτοκινης zcytor19
CY1118115T1 (el) Υποδοχεας κυτοκινης zcytor17
DE60125543D1 (de) Löslicher zytokinrezeptor zalpha11
EA200100276A1 (ru) Рецептор цитокина zalpha11
CY1106382T1 (el) Αντισωματα anti-vegf
CY1109557T1 (el) ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΑΝΙΧΝΕΥΣΗΣ ΓΟΝΙΔΙΟΥ ΓΙΑ ΒΕΛΤΙΩΣΗ ΤΗΣ ΠΙΘΑΝΟΤΗΤΑΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΗΣ ΑΠΟΚΡΙΣΗΣ ΣΕ ΚΑΡΚΙΝΙΚΗ ΘΕΡΑΠΕΙΑ ΑΝΤΑΓΩΝΙΣΤΗ ErbB
CY1117786T1 (el) Διαφορικα εκφραζομενα σε ογκους γονιδιακα προϊοντα και χρηση αυτων
DE69332606D1 (de) In vitro aktivierung cytotoxischer t-zellen
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
ES2148173T3 (es) Proteinas de fusion de especificidad mixta.
CY1106070T1 (el) Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
DK368588A (da) Bindingsmolekyler med en enkelt polypeptidkaede
EP0845032A4 (en) ISOLATED NUCLEIC ACID MOLECULES, PEPTIDES FORMING COMPLEXES WITH THE MOLECULE OF THE MAJOR HLA-A2 HISTOCOMPATIBILITY COMPLEX (MHC) AND THEIR APPLICATIONS
CY1112236T1 (el) Πεπτιδια που ειναι σε θεση να αναστελλουν την αλληλεπιδραση μεταξυ των πρεσενιλινων και του βητα-αμυλοειδους πεπτιδιου ή του προδρομου
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.
CY1106525T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
DE60230822D1 (de) Peptide mit homing für lymphgefässtumor und ihre verwendung
ATE298003T1 (de) Ein tumorsuppressor namens ts10q23.3
PT977859E (pt) O factor neurotrofico nnt-1